| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802703501031 | 270350103 | TOPEPIL F.C.TAB 25MG/TAB BTx1 BOTTLE (HDPE) x60 TABS (HDPE) x60 TABS | 4.17 | 4.37 | 06.02 |
| 05/2018 | 2802703502038 | 270350203 | TOPEPIL F.C.TAB 50MG/TAB BTx1 BOTTLE (HDPE) x60 TABS (HDPE) x60 TABS | 7.62 | 7.99 | 11.01 |
| 05/2018 | 2802703503035 | 270350303 | TOPEPIL F.C.TAB 100MG/TAB BTx1 BOTTLE (HDPE) x60 TABS | 13.02 | 13.66 | 18.83 |
| 05/2018 | 2802703504032 | 270350403 | TOPEPIL F.C.TAB 200MG/TAB BTx1 BOTTLE (HDPE) x60 TABS | 25.11 | 26.34 | 36.29 |
Used for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures and also for the prevention of migraine headaches. In children it is also used for treatment of Lennox-Gastaut syndrome.
The precise mechanism of action of topiramate is not known. However, studies have shown that topiramate blocks the action potentials elicited repetitively by a sustained depolarization of the neurons in a time-dependent manner, suggesting a state-dependent sodium channel blocking action. Topiramate also augments the activity of the neurotransmitter gamma-aminobutyrate (GABA) at some subtypes of the GABA<sub>A</sub> receptor (controls an integral chloride channel), indicating a possible mechanism through potentiation of the activity of GABA. Topiramate also demonstrates antagonism of the AMPA/kainate subtype of the glutamate excitatory amino acid receptor. It also inhibits carbonic anhydrase (particularly isozymes II and IV), but this action is weak and unlikely to be related to its anticonvulsant actions.
Symptoms of overdose include abdominal pain, agitation, blurred vision, convulsions, depression, dizziness, double vision, drowsiness, impaired coordination, impaired mental activity, low blood pressure, reduced consciousness, severe diarrhea, sluggishness, and speech problems.
Rapid with pleak plasma concentrations occurring after 2 hours and a bioavailability of 80%.
19 to 23 hours
Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose).
* Oral plasma cl=20 - 30 mL/min [in humans following oral administration]